MedTrace Logo

Thymoquinone as an add-on Therapy for the Management of Patients With Diabetic Peripheral Neuropathy

NCT07313111 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2025-12-31

No results posted yet for this study

Summary

The goal of this clinical trial is to evaluate the efficacy of thymoquinone as an adjuvant treatment with pregabalin in the management of diabetic peripheral neuropathy for both sexes older than 18 years.

The main questions it aims to answer are:

* Whether the use of thymoquinone could improve diabetic neuropathy and be confirmed by a nerve conduction study?
* Could thymoquinone improve oxidative stress and inflammation by using these parameters (visfatin, calprotectin, malondialdehyde)?
* Does thymoquinone improve neuropathic pain by using the VAS scale for pain?

Conditions

  • Diabetic Peripheral Neuropathy (DPN)

Interventions

DRUG

stander treatment pregabalin

Participants received 75 mg of a pregabalin capsule for two months

DIETARY_SUPPLEMENT

thymoquinone

participants recieved 65 mg of thymoquinone capsule daily for two months

Sponsors & Collaborators

  • Hawler Medical University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-07-01
Primary Completion
2025-09-01
Completion
2025-09-01

Countries

  • Iraq

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07313111 on ClinicalTrials.gov